Abstract
MET (hepatocyte growth factor receptor) and RON (recepteur dorigine Nantaise) are members of the MET proto-oncogene family of receptor tyrosine kinases (RTKs). Signalling from MET or RON activates multiple signalling pathways and ultimately promotes tumorigenesis and the formation of metastases. Mutations in MET have been detected in abundance in squamous cell carcinoma of the head and neck (SCCHN) metastases relative to the primary tumour, suggesting that this is a critical oncogene regulating dissemination. The biological significance of RON in SCCHN is still relatively unexplored. As survival has plateaued for patients with SCCHN, novel therapies with effects on the primary tumour and metastatic disease are urgently required. Small molecule inhibition of MET has been achieved in the pre-clinical setting and future clinical development is an exciting prospect. In this review, we summarise the biology of MET and RON RTKs and their contribution to an invasive tumour phenotype. We highlight their potential as therapeutic targets and address putative roles for MET and RON in resistance to conventional therapy, with particular reference to SCCHN.
Keywords: MET, RON, tyrosine kinase, squamous cell carcinoma of the head and neck, hepatocyte growth factor, macrophage stimulating protein, metastasis, small molecule tyrosine kinase inhibitors
Current Enzyme Inhibition
Title: MET and RON Receptor Tyrosine Kinases: Novel Therapeutic Targets in Squamous Cell Carcinoma of the Head and Neck
Volume: 3 Issue: 1
Author(s): Susanne J. Rogers, Carol Box, Christopher M. Nutting, Peter Rhys Evans, Kevin J. Harrington and Suzanne A. Eccles
Affiliation:
Keywords: MET, RON, tyrosine kinase, squamous cell carcinoma of the head and neck, hepatocyte growth factor, macrophage stimulating protein, metastasis, small molecule tyrosine kinase inhibitors
Abstract: MET (hepatocyte growth factor receptor) and RON (recepteur dorigine Nantaise) are members of the MET proto-oncogene family of receptor tyrosine kinases (RTKs). Signalling from MET or RON activates multiple signalling pathways and ultimately promotes tumorigenesis and the formation of metastases. Mutations in MET have been detected in abundance in squamous cell carcinoma of the head and neck (SCCHN) metastases relative to the primary tumour, suggesting that this is a critical oncogene regulating dissemination. The biological significance of RON in SCCHN is still relatively unexplored. As survival has plateaued for patients with SCCHN, novel therapies with effects on the primary tumour and metastatic disease are urgently required. Small molecule inhibition of MET has been achieved in the pre-clinical setting and future clinical development is an exciting prospect. In this review, we summarise the biology of MET and RON RTKs and their contribution to an invasive tumour phenotype. We highlight their potential as therapeutic targets and address putative roles for MET and RON in resistance to conventional therapy, with particular reference to SCCHN.
Export Options
About this article
Cite this article as:
Rogers J. Susanne, Box Carol, Nutting M. Christopher, Rhys Evans Peter, Harrington J. Kevin and Eccles A. Suzanne, MET and RON Receptor Tyrosine Kinases: Novel Therapeutic Targets in Squamous Cell Carcinoma of the Head and Neck, Current Enzyme Inhibition 2007; 3 (1) . https://dx.doi.org/10.2174/157340807779815404
DOI https://dx.doi.org/10.2174/157340807779815404 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient
Current Drug Targets Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth,Angiogenesis and Metastasis
Current Pharmaceutical Design Development and Clinical Application of Tumor-derived Exosomes in Patients with Cancer
Current Stem Cell Research & Therapy Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets Screening of Hub Gene Targets for Lung Cancer via Microarray Data
Combinatorial Chemistry & High Throughput Screening Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Synthesis, Preferentially Hypoxic Apoptosis and Anti-Angiogenic Activity of 3- Amino-1,2,4-Benzotriazine-1,4-Dioxide Bearing Alkyl Linkers with a 3-Amino-1,2,4- Benzotriazine-1-Oxide Moiety
Anti-Cancer Agents in Medicinal Chemistry Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Some Developments Regarding Functional Food Products (Functional Foods)
Current Nutrition & Food Science Scaffold Vascularization: A Challenge for Three-Dimensional Tissue Engineering
Current Medicinal Chemistry Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies
Current Drug Delivery An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA